Regulatory Effects of Lactobacillus crispatus and Lactobacillus rhamnosus on the Formation and Composition of Gardnerella Biofilms
In an in vitro model, L. crispatus and L. rhamnosus reduce Gardnerella biofilm formation, with a direction favorable to inhibition, but complete statistical magnitude data were not available in the provided text.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Gardnerella biofilm formation (crystal violet density) | D | ▲ Favorable | Absorbance at 595 nm; direction of inhibition reported, exact values and 95% CI not available in provided text excerpt | 1 |
| Biofilm ultrastructural morphology (scanning electron microscopy) | D | — Insufficient | Qualitative SEM comparison only; no quantitative metric reported | 1 |
| Lactic acid production by Lactobacillus (D- and L-isomer profile) | D | — Insufficient | Metabolic profiling reported as background; quantitative inhibitory values not extracted in provided text | 1 |
| Variability of biofilm formation among Gardnerella strains | D | — Insufficient | Descriptive classification (strong vs weak formers by OD595); no comparative statistic with CI reported in available text | 1 |
Context
Bacterial vaginosis (BV) affects approximately 30% of reproductive-age women worldwide, with recurrence rates exceeding 50% within one year after metronidazole treatment. Gardnerella biofilms are identified as a central mechanism of recurrence by shielding pathogenic bacteria from antibiotic penetration. Investigating specific Lactobacillus strains as antibiofilm agents is clinically relevant given the absence of therapies that restore L. crispatus dominance.
What the study showed
The study isolated 24 Gardnerella strains and 30 Lactobacillus strains from clinical vaginal samples. All Gardnerella strains formed biofilms, with marked variability between weak and strong biofilm-forming strains (classified by absorbance at 595 nm). L. crispatus and L. rhamnosus demonstrated inhibitory capacity on Gardnerella biofilm formation in in vitro co-culture. Absolute absorbance values, 95% CI, and precise effect sizes were not reported in the provided text, precluding complete quantification of magnitude.
How it was done
Experimental in vitro study with a clinical isolation component. Vaginal samples were collected from women with BV and healthy controls at a single center (Beijing, China). Strains were identified by 16S rDNA sequencing and BLAST. Biofilms were quantified by crystal violet staining in 96-well microplates after 48h anaerobic incubation at 37°C; structure was assessed by scanning electron microscopy (SEM) in four selected strains (G1, G2 strong biofilm; G23, G24 weak biofilm).
Effect magnitude
The provided text does not report complete statistical values (95% CI, RR, OR, SMD, or MD) for biofilm inhibition outcomes. Magnitude assessment is limited by the absence of this section in the available excerpt.
Limitations
Exclusively in vitro design (96-well microplate model) without validation in animal models or clinical trials, limiting extrapolation to the vaginal environment. Single recruitment center (Beijing) restricts geographic and ethnic representativeness. Gardnerella identification only to genus level (16S rDNA insufficient for species), missing interspecies virulence heterogeneity. Absence of randomization, blinding, and formal control group in the experimental component — applicable risk of bias tool: ROBINS-I for the observational isolation component; non-standardized in vitro bias risk. Limited biological replicates (triplicate per strain) without formal power calculation.
In clinical practice
This study does NOT provide sufficient evidence to modify clinical practice. Clinicians should not prescribe L. crispatus or L. rhamnosus as metronidazole substitutes based on these in vitro data. The finding reinforces the mechanistic hypothesis that specific Lactobacillus strains can interfere with Gardnerella biofilms, justifying the design of randomized clinical trials.
What is still missing
Randomized clinical trials evaluating the efficacy of probiotics containing clinically isolated L. crispatus on BV cure and recurrence rates at 6–12 months. Dose-response and strain stability studies in the in vivo vaginal environment are required before any clinical translation.